Key points are not available for this paper at this time.
Despite advances in HER2-targeted treatments, patients with CNS metastasis continue to have a poor prognosis and impaired quality of life. Observation of CNS metastasis appears to influence HER2-targeted treatment choice.
Hurvitz et al. (Fri,) studied this question.